| Literature DB >> 23134227 |
Stefania Sartini1, Sandro Cosconati, Luciana Marinelli, Elisabetta Barresi, Salvatore Di Maro, Francesca Simorini, Sabrina Taliani, Silvia Salerno, Anna Maria Marini, Federico Da Settimo, Ettore Novellino, Concettina La Motta.
Abstract
Diabetes mellitus is the major risk factor for cardiovascular disorders. Aldose reductase, the rate-limiting enzyme of the polyol pathway, plays a key role in the pathogenesis of diabetic complications. Accordingly, inhibition of this enzyme is emerging as a major therapeutic strategy for the treatment of hyperglycemia-induced cardiovascular pathologies. In this study, we describe a series of 5(6)-substituted benzofuroxane derivatives, 5a-k,m, synthesized as aldose reductase inhibitors. Besides inhibiting efficiently the target enzyme, 5a-k,m showed additional NO donor and antioxidant properties, thus emerging as novel multi-effective compounds. The benzyloxy derivative 5a, the most promising of the whole series, showed a well-balanced, multifunctional profile consisting of submicromolar ALR2 inhibitory efficacy (IC50=0.99±0.02 μM), significant and spontaneous NO generation properties, and excellent hydroxyl radical scavenging activity. Computational studies of the novel compounds clarified the aldose reductase inhibitory profile observed, thus rationalizing structure-activity relationships of the whole series.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23134227 DOI: 10.1021/jm301124s
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446